- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01140087
Face Transplantation
Maxillofacial Composite Tissue Allograft Transplantation: Face Transplant
This study aims to:
- Perform face transplants on people who have suffered severe facial trauma with tissue and functional loss; and
- Evaluate the acceptance and function of the transplanted tissue.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
For patients with severe facial deformities or facial wounds from traumatic injuries, we would like to pursue the use of a face transplant to help reconstruct a person's damaged face. Our goal is to not only give the patient back a normal appearance to their face but also the functioning, movement, and sensation of their face including that of the lips, mouth, and eyes. For some patients with severe face deformities simple tasks such as smiling, talking, eating, kissing a loved one, or even just being able to contain their saliva become difficult, if not impossible. These patients often become depressed because of their facial deformities.
Although there are some techniques in plastic and reconstructive surgery that can repair the look of a patient's face, often these cannot replace the moving parts of the face. Currently, patients with severe facial deformities would undergo several reconstructive surgeries with their own tissues, called autologous transplant. This surgery often leaves unacceptable scars and deformities of the patient's donor sites. Also, this conventional reconstruction method requires many returns to the operating room to carefully form and shape the transplanted free flap. Lastly, this type of reconstruction is still limited, as it does not provide a reliable return in function, sensation, and appearance for the damaged parts of the face.
Instead, if we use a composite tissue allograft (CTA), or face transplant from a donor who is brain dead such as in heart, kidney and liver transplants, we could replace the damaged parts of the face with the same missing parts that could return movement as well. However, since the transplanted facial tissues are from another person, these face transplant recipients need medicines that would keep their body from rejecting the new tissues. This new course of medicines would be their daily responsibility. Though there are risks with taking these medicines, the risks have been lowered by many prior studies that have been done with patients who have had other organ transplants. However, the risks are still a consideration when deciding to choose this option for correcting severe facial deformities.
This study aims to perform a face transplant on a person who has suffered a severe facial trauma with tissue and functional loss, and with limited other established surgical options to repair their deformities. We will conduct the surgery and prospectively follow the patient to monitor his or her clinical and functional outcomes and ensure that optimal results are achieved. We will systematically document and record the entire process of the patient's surgery and recovery. An important factor of this surgery's success is that the patient strictly follows and takes the required course of medicines to prevent rejection of the donor tissues. In order to ensure that the tissue survives and is not rejected by the patient, we will continuously check various clinical values, such as blood work, tissue samples, and x-ray images.
We would like to offer facial segment transplantation as a reconstructive option to patients with severe facial deformities. We feel facial transplantation has now become a viable option for certain patients. If successful, this will contribute to future research and development in the field of tissue transplantation. Most importantly, our goal is to offer patients the best option in reconstruction to restore both form and function who otherwise do not have another option.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- University of Maryland, Baltimore
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18-64 years of age
- Facial defect or injury requiring facial transplantation as determined by the treating Plastic and Reconstructive Surgeon
- Signed written informed consent
- Able to complete psychiatric evaluations
- Willing and able to continue immunosuppression regimen as directed by treating physician
- Willing and able to return for follow-up visits as described in the treatment plan
- Must have autogenous tissue options available for reconstruction in event of graft failure
- Laboratory values as defined by research protocol
- Willing to undergo review by Participant Selection Committee and be placed on a transplant recipient waitlist
Exclusion Criteria:
- Pre-existing disease that would exclude the recipient from transplantation
- Active infection
- Ongoing substance abuse
- HIV positive
- Positive for Hepatitis B or C
- Active malignancy
- Pregnant or breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Interventional
Face Transplantation
|
Transplantation of donor facial skin, tissue, muscle, and bone as needed
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate the success of the face transplant
Time Frame: Monthly for 6 months, every 6 months for 2 years, then annually
|
We will measure the restoration of function, sensation, and appearance of the transplanted facial segment
|
Monthly for 6 months, every 6 months for 2 years, then annually
|
Collaborators and Investigators
Investigators
- Principal Investigator: Rolf Barth, MD, U of Maryland
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- HP-00040219
- N00014-07-1-0298 (OTHER_GRANT: ONR)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Transplantation: Facial Transplantation
-
Methodist Health SystemCompleted
-
Astellas Pharma Europe Ltd.Active, not recruitingLiver Transplantation | Kidney Transplantation | Heart Transplantation | Lung Transplantation | Intestine TransplantationBelgium, Czechia, France, Germany, Italy, Poland, United Kingdom
-
Astellas Pharma IncAstellas Pharma Europe B.V.CompletedKidney Transplantation | Renal Transplantation | Transplantation, Kidney | Grafting, Kidney | Transplantation, RenalBelgium, Germany, Spain, Sweden, Italy, Switzerland, United Kingdom, Austria, France, Poland, Czech Republic, Netherlands
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCzechia, France, Italy, Poland, United Kingdom
-
The Hospital for Sick ChildrenCompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCanada
-
Astellas Pharma Europe Ltd.TerminatedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationSpain, Australia, France, Germany, Canada, Italy, United Kingdom, Belgium, South Africa, Switzerland, Sweden, United States, Austria, Brazil, Czechia, Denmark, Finland, Hungary, Ireland, Mexico, Netherlands, New Zealand, Poland
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Astellas Pharma IncCompletedHeart Transplantation | Lung Transplantation | Pancreas (Including SPK) TransplantationFrance, United Kingdom, Taiwan, Belgium, Italy, Austria
-
Emory UniversityCompletedLiver Transplantation | Kidney Transplantation | Heart Transplantation | Lung Transplantation | Heart-Lung TransplantationUnited States
Clinical Trials on Face Transplant
-
The Cleveland ClinicUnited States Department of DefenseCompleted
-
Andalusian School of Public HealthCompleted
-
Kayseri City HospitalTC Erciyes UniversityNot yet recruitingLearning | Exercise Test
-
Social Insurance Institution, FinlandActive, not recruitingInformal Caregivers | Caregivers | Family CaregiversFinland
-
University of NottinghamImperial College London; University College, London; Retroscreen Virology Ltd.Withdrawn
-
University Hospital, Clermont-FerrandSENS laboratory, Univ. Grenoble Alpes; INRAE, UNH, CRNH Auvergne, Clermont... and other collaboratorsCompletedObesity | Diabete Type 2France
-
Ahi Evran University Education and Research HospitalCompleted
-
Pacific Northwest University of Health SciencesAmerican Association of Colleges of Osteopathic Medicine - AACOMCompleted
-
National Institute of Medical Sciences and Nutrition...CompletedImpact of a Hybrid Medical Care Model in the Rheumatoid Arthritis Patient-reported-outcomes MeasuresRheumatoid Arthritis | TelehealthMexico
-
University of BirminghamHeart of England NHS Trust; Calderdale and Huddersfield NHS Foundation Trust; Resuscitation Council UKCompletedCardiac Arrest